# Understanding Eosinophil Heterogeneity: The Known and Unknown

**Authors:** Alexander Ruzic, Michael Trus, Roma Sehmi, Manali Mukherjee

PMC · DOI: 10.3390/cells15060564 · 2026-03-21

## TL;DR

This review explores how eosinophils, a type of immune cell, vary in function and traits across different disease states, and how this impacts treatment decisions in chronic airway diseases.

## Contribution

The paper introduces an integrative framework for understanding eosinophil heterogeneity as a continuum of activation rather than fixed subsets.

## Key findings

- Eosinophils show phenotypic and functional diversity across tissues and diseases.
- Transcriptomic and proteomic studies reveal that functional specialization occurs in inflamed tissues, not in peripheral blood.
- CD62L-based subtyping has limitations in specificity and clinical relevance for human eosinophils.

## Abstract

Eosinophils are multifunctional granulocytes with central roles in the pathobiology of chronic airway diseases. While systemic eosinophilia (>300 cells/μL) is a well-established biomarker to guide therapeutic decision-making, accumulating evidence indicates that eosinophils are not a uniform population but instead exhibit substantial phenotypic and functional heterogeneity across biological compartments, inflammatory states, and disease contexts. In this review, we synthesize the current understanding of eosinophil heterogeneity in airway diseases and critically evaluate the strengths and limitations of surface marker-based approaches, with emphasis on CD62L/L-selectin-defined subpopulations. Although CD62L-based stratification has provided valuable insight into eosinophil activation and tissue localization, its limited specificity, inconsistent clinical associations, and reliance on murine models restrict its utility as a framework for eosinophil subtyping in humans. We highlight how transcriptomic and proteomic profiling has transformed the field by revealing that peripheral blood eosinophils are largely quiescent, whereas disease-relevant functional specialization is predominantly acquired within inflamed tissues in response to cues from the local microenvironment. These molecular studies support a model in which eosinophil heterogeneity represents a continuum of activation rather than discrete, fixed subsets. A refined, integrative approach to understanding eosinophil heterogeneity is critical for improving patient stratification, predicting therapeutic responsiveness, and optimizing precision medicine strategies in chronic airway diseases.

## Linked entities

- **Proteins:** SELL (selectin L), Sell (selectin, lymphocyte)

## Full-text entities

- **Genes:** CCL4L2 (C-C motif chemokine ligand 4 like 2) [NCBI Gene 9560] {aka AT744.2, CCL4L, SCYA4L, SCYQ4L2}, CEBPA (CCAAT enhancer binding protein alpha) [NCBI Gene 1050] {aka C/EBP-alpha, CEBP}, IL13 (interleukin 13) [NCBI Gene 3596] {aka IL-13, P600}, GATA1 (GATA binding protein 1) [NCBI Gene 2623] {aka CNSHA9, ERYF1, GATA-1, GF-1, GF1, HAEADA}, CD63 (CD63 molecule) [NCBI Gene 967] {aka AD1, HOP-26, ME491, MLA1, OMA81H, Pltgp40}, CCL11 (C-C motif chemokine ligand 11) [NCBI Gene 6356] {aka SCYA11}, SIGLEC8 (sialic acid binding Ig like lectin 8) [NCBI Gene 27181] {aka SAF2, SIGLEC-8, SIGLEC8L}, CCL24 (C-C motif chemokine ligand 24) [NCBI Gene 6369] {aka Ckb-6, MPIF-2, MPIF2, SCYA24}, CCL26 (C-C motif chemokine ligand 26) [NCBI Gene 10344] {aka IMAC, MIP-4a, MIP-4alpha, SCYA26, TSC-1}, Sell (selectin, lymphocyte) [NCBI Gene 20343] {aka CD62L, L-selectin, LAM-1, LECAM-1, LECAM1, Lnhr}, CD101 (CD101 molecule) [NCBI Gene 9398] {aka EWI-101, IGSF2, V7}, MBP (myelin basic protein) [NCBI Gene 4155], ITGAM (integrin subunit alpha M) [NCBI Gene 3684] {aka CD11B, CR3A, HNA-4, MAC-1, MAC1A, MO1A}, OXER1 (oxoeicosanoid receptor 1) [NCBI Gene 165140] {aka GPCR, GPR170, TG1019}, ALOX15 (arachidonate 15-lipoxygenase) [NCBI Gene 246] {aka 12-LOX, 15-LOX, 15-LOX-1, LOG15}, CD34 (CD34 molecule) [NCBI Gene 947], SPI1 (Spi-1 proto-oncogene) [NCBI Gene 6688] {aka AGM10, OF, PU.1, SFPI1, SPI-1, SPI-A}, TSLP (thymic stromal lymphopoietin) [NCBI Gene 85480], CCR3 (C-C motif chemokine receptor 3) [NCBI Gene 1232] {aka C C CKR3, CC-CKR-3, CD193, CKR 3, CKR3, CMKBR3}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, CD86 (CD86 molecule) [NCBI Gene 942] {aka B7-2, B7.2, B70, BU63, CD28LG2, CD86 v6}, SIGLEC10 (sialic acid binding Ig like lectin 10) [NCBI Gene 89790] {aka PRO940, SIGLEC-10, SLG2}, RNASE3 (ribonuclease A family member 3) [NCBI Gene 6037] {aka ECP, RAF1, RNS3}, Anpep (alanyl aminopeptidase, membrane) [NCBI Gene 16790] {aka AP-M, AP-N, Apn, Cd13, P150}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, ADGRE1 (adhesion G protein-coupled receptor E1) [NCBI Gene 2015] {aka EMR1, TM7LN3}, CD14 (CD14 molecule) [NCBI Gene 929], CLC (Charcot-Leyden crystal galectin) [NCBI Gene 1178] {aka GAL10, Gal-10, LGALS10, LGALS10A, LPPL_HUMAN}, IL5RA (interleukin 5 receptor subunit alpha) [NCBI Gene 3568] {aka CD125, CDw125, HSIL5R3, IL5R}, LUM (lumican) [NCBI Gene 4060] {aka LDC, SLRR2D}, Il3ra (interleukin 3 receptor, alpha chain) [NCBI Gene 16188] {aka CD123, CDw123, SUT-1}, IFNA1 (interferon alpha 1) [NCBI Gene 3439] {aka IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA13, IFNA@}, ATN1 (atrophin 1) [NCBI Gene 1822] {aka B37, CHEDDA, D12S755E, DRPLA, HRS, NOD}, ITGB2 (integrin subunit beta 2) [NCBI Gene 3689] {aka CD18, LAD, LCAMB, LFA-1, MAC-1, MF17}, RNASE2 (ribonuclease A family member 2) [NCBI Gene 6036] {aka EDN, RAF3, RNS2}, CD69 (CD69 molecule) [NCBI Gene 969] {aka AIM, BL-AC/P26, CLEC2C, EA1, GP32/28, MLR-3}, VCAM1 (vascular cell adhesion molecule 1) [NCBI Gene 7412] {aka CD106, INCAM-100}, FUT4 (fucosyltransferase 4) [NCBI Gene 2526] {aka CD15, ELFT, FCT3A, FUC-TIV, FUTIV, LeX}, CSF2 (colony stimulating factor 2) [NCBI Gene 1437] {aka CSF, GMCSF}, SELL (selectin L) [NCBI Gene 6402] {aka CD62L, LAM1, LECAM1, LEU8, LNHR, LSEL}, ITGAX (integrin subunit alpha X) [NCBI Gene 3687] {aka CD11C, SLEB6}, IL5 (interleukin 5) [NCBI Gene 3567] {aka EDF, IL-5, TRF}, CEACAM8 (CEA cell adhesion molecule 8) [NCBI Gene 1088] {aka CD66b, CD67, CGM6, NCA-95}, EPX (eosinophil peroxidase) [NCBI Gene 8288] {aka EPO, EPP, EPX-PEN, EPXD}, Nr4a1 (nuclear receptor subfamily 4, group A, member 1) [NCBI Gene 15370] {aka GFRP1, Gfrp, Hbr-1, Hbr1, Hmr, N10}, CXCR6 (C-X-C motif chemokine receptor 6) [NCBI Gene 10663] {aka BONZO, CD186, CDw186, STRL33, TYMSTR}, IL3RA (interleukin 3 receptor subunit alpha) [NCBI Gene 3563] {aka CD123, IL-3R-alpha, IL3R, IL3RAY, IL3RX, IL3RY}, CD28 (CD28 molecule) [NCBI Gene 940] {aka IMD123, Tp44}, ANXA1 (annexin A1) [NCBI Gene 301] {aka ANX1, LPC1}, IL18 (interleukin 18) [NCBI Gene 3606] {aka IGIF, IL-18, IL-1g, IL1F4}, IL33 (interleukin 33) [NCBI Gene 90865] {aka C9orf26, DVS27, IL1F11, NF-HEV, NFEHEV}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, CCL3L1 (C-C motif chemokine ligand 3 like 1) [NCBI Gene 6349] {aka 464.2, D17S1718, G0S19-2, LD78, LD78-beta(1-70), LD78BETA}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, SELP (selectin P) [NCBI Gene 6403] {aka CD62, CD62P, GMP140, GRMP, LECAM3, PADGEM}
- **Diseases:** airway inflammation (MESH:D007249), airway and allergic diseases (MESH:D004342), CRSwNP (MESH:D009298), immune dysregulation (OMIM:614878), Asthma (MESH:D001249), eosinophilia (MESH:D004802), tissue injury (MESH:D017695), type 2-low disease (MESH:D009800), -2 (MESH:D020803), wheeze (MESH:D012135), acute lung injury (MESH:D055371), EoE (MESH:D057765), chronic rhinosinusitis (MESH:D000092562), EA (MESH:C580065), acute respiratory distress syndrome (MESH:D012128), COPD (MESH:D029424), gastrointestinal disorders (MESH:D005767), reduced (MESH:D001523), Obstructive Lung Diseases (MESH:D008173), asthmatic (MESH:D013224), eosinophilic complications (MESH:D017681), EGPA (MESH:D014890), disease (MESH:D004194), airway infection (MESH:D007239), injury to (MESH:D014947), -1 (MESH:C538557)
- **Chemicals:** LPS (MESH:D008070), ATP (MESH:D000255), mepolizumab (MESH:C434107), GTP (MESH:D006160), ROS (MESH:D017382), lipid (MESH:D008055), dupilumab (MESH:C582203), eosin (MESH:D004801), benralizumab (MESH:C571386), Tezepelumab (MESH:C000622721), ICS (-)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC13025715/full.md

---
Source: https://tomesphere.com/paper/PMC13025715